HOME
CAREERS
CONTACT US
KOREAN
ENGLISH
KR
EN
Toggle navigation
COMPANY
ABOUT US
KEY MEMBERS
HISTORY
BOARD OF DIRECTORS
SCIENTIFIC ADVISORY BOARD
SCIENCE
PIPELINE
COLLABORATION
INVESTORS
NOTICE
PRESENTATION
GENERAL MEETING
OF STOCKHOLDERS
INDEPENDENT
AUDITOR'S REPORT
CONTACT IR
MEDIA
NEWS
VIDEO SOURCE
ESG
OVERVIEW
ENVIRONMENTAL
SOCIAL
GOVERNANCE
NEWS
HOME
MEDIA
NEWS
NEWS
Total
79
59
NeoImmuneTech to Present at Immuno-Oncology Summit Europe 2022
2022-05-19
58
NeoImmuneTech Received U.S. FDA Clearance of IND Application for Phase II Study of NT-I7 and Pembrolizumab in Recurrent Glioblastoma
2022-05-11
57
NeoImmuneTech to Show Significant Advances on NT-I7 (efineptakin alfa) at 2022 ASCO Annual Meeting
2022-04-28
56
NeoImmuneTech Demonstrates NT-I7’s Broad Combination Potential with Immune Checkpoint Inhibitors and Immunocytokine at AACR 2022
2022-04-14
55
NeoImmuneTech to Celebrate First Year of Trading at KOSDAQ
2022-03-16
54
NeoImmuneTech to Present Two Posters at American Association for Cancer Research Annual Meeting
2022-03-10
53
NeoImmuneTech to Present at Upcoming Business Conferences
2022-02-09
52
NeoImmuneTech Announces First Patient Dosed in Phase 2 Study of NT-I7 (efineptakin alfa) with PD-L1 checkpoint inhibitor in High-Risk Skin Cancers
2022-02-07
51
Preclinical Data on NT-I7 Published in Clinical Cancer Research
2022-01-24
50
NeoImmuneTech to Present at 2022 Biotech Showcase at J.P. Morgan Healthcare Conference
2022-01-05
1
2
3
4
5
>
>>
Search